Filter By Category
Archives
Share on -
APADAMTASE ALFA
Generic Name: APADAMTASE ALFA
ABSTRACT -
Apadamtase alfa is recombinant human ADAMTS13, marketed as ADZYNMA in some regions.
It is enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP), used for prophylactic and on-demand treatment.
It replaces deficient ADAMTS13 activity to cleave ultra-large von Willebrand factor multimers and reduce microvascular thrombosis.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- For prophylaxis, the recommended regimen is commonly 40 IU/kg intravenously every other week.
- The frequency may be adjusted to 40 IU/kg once weekly based on prior prophylaxis or clinical response.
- On-demand acute-event dosing must follow the approved label and specialist hematology guidance.
SIDE EFFECTS–
- Possible side effects may include:
- Headache
- Diarrhea
- Migraine
- Abdominal pain
- Nausea
- Upper respiratory tract infection
- Hypersensitivity
- Development of neutralizing antibodies is a potential risk
ALLRGIC REACTIONS–
- Hypersensitivity to the active biologic or formulation excipients is possible.
- Symptoms may include rash, urticaria, pruritus, facial swelling, bronchospasm, fever, chills, hypotension, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Formal drug interaction data are limited.
- Plasma products may affect ADAMTS13 activity assessment and treatment planning.
- Concomitant anticoagulants or antiplatelets should be reviewed because bleeding and thrombosis risks vary by clinical state.
PREAUTIONS–
- Confirm cTTP diagnosis and baseline ADAMTS13 activity.
- Monitor for hypersensitivity and neutralizing antibodies if response is reduced.
- Track platelet counts, hemolysis markers, and organ symptoms during acute episodes.
- Use aseptic reconstitution and intravenous administration.
WARNINGS –
- Serious hypersensitivity can occur.
- Loss of efficacy may occur if neutralizing antibodies develop.
- Untreated acute cTTP can be life-threatening and requires urgent specialist care.
Share on -
. Developed by